Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards

European Journal of Health Economics

Volumn 5, Issue 1, 2004, Pages 64-69

  Ruof, Jörg ^a   Hülsemann, Jan L ^a   Mittendorf, Thomas ^a,b   Handelmann, Silke ^a   Aultman, Rick ^b   Von Der Schulenburg, J Matthias ^b   Zeidler, Henning ^a   Merkesdal, Sonja ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Cost of illness; Health economics; Rheumatoid arthritis

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MIDDLE AGED;

EID: 1542284168     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-003-0203-4     Document Type: Review

References (17)

1. Etzioni R, Riley GF, Ramsey SD, Brown, M (2002) Measuring costs. Administrative claims data, clinical trials, and beyond. Med Care 40 [Suppl III]:63-72
2. Luce BR, Manning WG, Siegel JE, Lipscomb J (1996) Estimating costs in cost-effectiveness analysis. In: Gold MR, Russell LB, Siegel JE, Weinstein MC (eds) Cost-effectiveness in health and medicine. Oxford University Press: Oxford
3. Ruof J, Huelsemann JL, Stucki L (1999) Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol 11:104-109
4. Ruof J, Merkesdal S, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, Zeidler H (2001) Cost assessment instruments in rheumatology: evaluation of applied instrument characteristics. J Rheumatol 28:662-665
5. Ferber von L, Ihle P (1997) Analyse von Krankenkassendaten zur ambulanten Versorgung von Patienten mit chronischer Polyarthritis. Akt Rheumatol 22:513-518
6. Ferber von L, Koester I, Hauner H (1997) Eine Krankheitskostenstudie zum Diabetes mellitus. Gesundheitswesen 59:17-22
7. Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52:199-207
8. World Health Organization (1992) International classification of diseases and related health problems, 10th revision, vol 1. WHO: Geneva
9. Ruof J, Huelsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, Merkesdal S (2003) Costs of rheumatoid arthritis in Germany. A micro-costing approach based on objective data sources. Ann Rheum Dis 62:544-550
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al (1988) The American Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
11. AOK-Die Gesundheitskasse für Niedersachsen (2001) Geschäftsbericht 2000. Grütter: Hanover
12. Merkesdal S, Ruof J, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, Zeidler H (2001) Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol 28:657-661
13. Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, Dreyer NA (1997) Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. Arthritis Rheum 40:1475-1481
14. Cook NR, Ware JH (1983) Design and analysis methods for longitudinal research. Annu Rev Public Health 4:1-23
15. Diggle PJ (1988) An approach to the analysis of repeated measurements. Biometrics 44:959-971
16. Gabriel SE, Wagner JL, Zinsmeister AR, Scott CG, Luthra HS (2001) Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists. Arthritis Rheum 44:1504-1514
17. Merkesdal S, Ruof J, Mittendorf T, Mau W, Zeidler H (2002) Health economic research in rheumatoid arthritis. Z Rheumatol 61:21-29